176-92-1 Usage
Uses
Used in Pharmaceutical Research:
1-Oxa-8-azaspiro[4.5]decane is used as a chiral auxiliary in asymmetric synthesis for the development of enantiomerically pure compounds, which are essential in the pharmaceutical industry to ensure the desired biological activity and minimize side effects.
Used in Organic Synthesis:
1-Oxa-8-azaspiro[4.5]decane is used as a precursor to various pharmacologically relevant compounds, contributing to the discovery and synthesis of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry:
1-Oxa-8-azaspiro[4.5]decane is utilized in the development of novel bioactive molecules, exploring its potential to enhance the properties of existing drugs or create new therapeutic agents with improved efficacy and safety profiles.
Used in Drug Design:
1-Oxa-8-azaspiro[4.5]decane serves as a valuable component in drug design, where its unique structural features can be exploited to create innovative molecules with specific biological targets, potentially leading to the development of more effective treatments for various diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 176-92-1 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,7 and 6 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 176-92:
(5*1)+(4*7)+(3*6)+(2*9)+(1*2)=71
71 % 10 = 1
So 176-92-1 is a valid CAS Registry Number.
InChI:InChI=1/C8H15NO/c1-2-8(10-7-1)3-5-9-6-4-8/h9H,1-7H2
176-92-1Relevant academic research and scientific papers
SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS
-
, (2009/12/05)
This invention relates to a new sordarin derivative or a pharmaceutically acceptable salt thereof, which has antimicrobial activities (especially, antifungal activities), to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases in a human being or an animal.
4,4-Disubstituted cyclohexylamine NK1 receptor antagonists II
Cooper, Laura C.,Carlson, Emma J.,Castro, Jose L.,Chicchi, Gary G.,Dinnell, Kevin,Di Salvo, Jerry,Elliott, Jason M.,Hollingworth, Gregory J.,Kurtz, Marc M.,Ridgill, Mark P.,Rycroft, Wayne,Tsao, Kwei-Lan,Swain, Christopher J.
, p. 1759 - 1762 (2007/10/03)
A series of novel 4,4-disubstituted cyclohexylamines as NK1 receptor antagonists is described: modifications to the amine moiety retain NK1 receptor binding affinity whilst disrupting IKr affinity.
